70 traditional Chinese medicine companies disclosed performance forecasts, and more than half were positive!

According to statistics, as of now, more than 150 A-share pharmaceutical companies have disclosed their 2021 performance forecasts, including 70 traditional Chinese medicine companies
.
If pre-increase, turnaround, slight increase, and continued profit are positive, and pre-reduction, continued loss, first loss, and slight decrease are negative, the proportion of companies with positive performance in the traditional Chinese medicine industry accounted for more than half, or 56.
25%
.
Among these 70 traditional Chinese medicine companies, many companies are expected to double their performance in 2021, such as Kangenbei, Tasly, Dong'e Ejiao, Zuoli Pharmaceutical,
etc.
Among them, Conba expects to achieve a net profit of 1.
93 billion-2.
15 billion yuan attributable to shareholders of listed companies in 2021, an increase of 1.
48 billion-1.
7 billion yuan compared with the same period last year, an increase of 325%-375%
.
For the reasons for the pre-increase in performance, Conba explained from three aspects, including the main business, the provision for asset impairment and the impact of non-recurring gains and losses
.
The 2021 annual performance forecast disclosed by Dong E E Jiao also performed well
.
The company expects to achieve a net profit of 428 million to 475 million yuan attributable to shareholders of listed companies in 2021, an increase of 888% to 997% over the same period last year
.
Regarding the reasons for the changes in performance, Dong'e Ejiao said that the company adheres to the consumer-centric approach, focuses on customer growth and retention, accelerates product innovation, strengthens the transformation of scientific research results, and continuously releases brand productivity to achieve stable and healthy growth
.
Tasly expects to achieve a net profit attributable to shareholders of listed companies of 2.
38 billion to 2.
47 billion yuan in 2021, a year-on-year increase of 112% to 119% compared with 2020
.
The pre-increase in the company's current performance was mainly due to non-recurring profit and loss events such as the disposal of I-MAB equity by the company's holding subsidiary and the conversion of accounting methods.
Calculated according to the shareholding ratio of the subsidiary, the impact amount was 1.
73 billion yuan; after deducting non-recurring gains and losses The decrease in net profit of recurring gains and losses was mainly due to the impact of the provision for impairment of assets
.
In addition, Zuoli Pharmaceutical expects that the net profit attributable to shareholders of listed companies in 2021 will be 170 million to 187 million yuan, a year-on-year increase of 91.
44% to 110.
58%
.
The company stated that during the reporting period, based on the advantages of the three core products of Wuling Capsules, Bailing Tablets and Lingze Tablets entering the National Essential Medicines List, it adhered to the marketing strategy of "stabilizing self-operation, strong investment promotion, retail sales, and full modules".
Increased market investment and development coverage of terminal medical institutions have enabled the three companies to achieve rapid growth in operating income
.
Of course, some people are happy and some are sad
.
In 2021, there will also be many loss-making traditional Chinese medicine companies, such as Taiantang, Dali Pharmaceutical, and Guangyuyuan
.
Among them, Tai'an Tang's net profit attributable to its parent in 2021 is expected to be -788 million yuan to -798 million yuan
.
The main reason is that Taiantang will repay 900 million yuan of corporate bonds in 2021, resulting in insufficient investment in marketing liquidity and a sharp decline in operating income
.
In addition to the performance forecast, there are still a number of traditional Chinese medicine companies that have disclosed performance reports
.
For example, Pien Tze Huang released the 2021 annual performance report on January 19.
In 2021, the company achieved an operating income of 8.
026 billion yuan, a year-on-year increase of 23.
27%; the net profit attributable to the parent was 2.
433 billion yuan, a record high, a year-on-year increase of more than 45.
55%
.
The industry believes that with the continuous advancement of favorable policies for traditional Chinese medicine, the traditional Chinese medicine industry will face more development opportunities
.
The pharmaceutical industry analyst of Soochow Securities pointed out that traditional Chinese medicine has advantages in the treatment of chronic diseases.
In the context of aging and consumption upgrading, the consumption attributes of traditional Chinese medicine have prompted its rapid increase in volume; the national standard has been raised, the price of Chinese medicine decoction pieces has risen, and traditional Chinese medicine formula granules and OTC products The increase in price resulted in an increase in gross profit margin
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.